Lixa is ultimately focused on developing world-wide and cross-sector scalable resistance breakers that restore the effectiveness of: Any antibiotic, biocide or disinfectant. Against any resistant bacteria. In any infectious disease or bacterial problem

Aug 14, 2023 · Lixa, an emerging biotech startup based in Western Australia, is on a mission to resolve recurring microbial infections and contaminations by developing a novel approach that makes resistant bacteria vulnerable to antibiotics and the immune system again.

The coming together of this promising technology, deep scientific rigour and business building expertise catalysed the creation of Lixa in 2021. Today, the Lixa team is backed by the substantial scientific and commercial experience of their directors, investors and advisors.

Sep 1, 2022 · Lixa – founded in 2021 by Dr Angela Fonceca and Dr Maud Eijkenboom – is working to solve recurring, problematic microbial infections and contaminations and have just closed their first capital raising round of over $2 million.

Lixa exists to solve the global problem of antimicrobial resistance. We reinvent and develop the future of antimicrobial technologies for human, animal, plant, marine and industrial applications.

NeoX™ is Lixa's core platform technology that enables treatment of previously resistant and "untreatable" infections across bacterial species and antibiotic classes.

Jun 27, 2024 · Lixa is delighted to announce that we have received Human Research Ethics Committee (HREC) approval to commence our first human trial - a Phase I clinical trial assessing the safety and tolerability of NeoX™ in an inhaled formulation.

It’s important for us to acknowledge and recognise Lixa’s Boorloo (Perth) office is on Whadjuk Noongar Boodja (land). We respect and honour Elders, both past and present, and acknowledge their Native Title rights to Country, which holds the stories, traditions and living culture of …

Jul 5, 2023 · Lixa, an emerging biotech startup based in Western Australia, is on a mission to resolve recurring microbial infections and contaminations by developing a novel approach that makes resistant bacteria vulnerable to antibiotics and the immune system again.

We are open to partnerships across sectors and at different technology development stages. The Lixa technology is complementary to other antimicrobial approaches, where the combination becomes more potent in the face of antimicrobial resistance.